News

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Tirzepatide is the active ingredient in Lilly’s injectable diabetes drug Mounjaro and weight-loss drug Zepbound. Mounjaro previously was approved in China for diabetes treatment.
Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in ...
Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug Zepbound, can now meet present and projected national demand, the FDA said in a statement.
Eli Lilly & Co.’s Mounjaro gained Chinese regulatory approval for weight less than a month after a similar therapy from Novo Nordisk A/S, fueling competition in a nation that’s among the ...
Eli Lilly (LLY) stock rises as Chinese drug regulator approves its weight loss therapy, tirzepatide, for long-term weight management. Read more here.
On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight ...
Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why LLY stock is a buy.
Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.
A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...
Eli Lilly has won approval from Chinese regulators to sell its weight-loss treatment tirzepatide in the country, the company said in a social media post on Friday.
SHANGHAI (Reuters) -Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish ...